Moderna Inc on Thursday said its closely-watched experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but failed to show it was at least as effective as an approved vaccine versus less prevalent influenza B. Moderna, whose only marketed product is its COVID-19 shot, has high hopes for […]
The post Moderna flu vaccine delivers mixed results in trial, shares fall appeared first on Inquirer News.
Disclaimer : We make no assurance about the completeness and accuracy of the content of this website. All news on this website is collected from various sources hence information may or may not be true. Money Nations does not verify the reliability of the content published. We do not accept any accountability for loss or damage occurred as a result of reliability on the content of this website.
Subscribe to our newsletters now and stay
up-to-date with new articles and exclusive offers.
Your email is safe with us. We won't spam.